Acuta Capital Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Acuta Capital Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-27,500	Closed	-$1.3M	–	50
2022 Q2	$1.3M	Buy	27,500 +25,200	+1,096%	+$1.37M	0.72%	32
2022 Q1	$164K	Buy	+2,300	New	+$150K	0.08%	40
2019 Q2	–	Sell	-61,000	Closed	-$5.83M	–	35
2019 Q1	$5.83M	Buy	+61,000	New	+$5.47M	2.77%	14
2015 Q1	–	Sell	-44,528	Closed	-$2.26M	–	57
2014 Q4	$2.26M	Buy	+44,528	New	+$1.99M	1.53%	19

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Acuta Capital Partners's ENTA Position: Q3 2022 in Review

Acuta Capital Partners sold out of Enanta Pharmaceuticals (ENTA) in Q3 2022, closing a stake of 27,500 shares — an estimated $1.3M sold.

Acuta Capital Partners first reported a position in ENTA in Q4 2014 and held it in 4 quarters. The position peaked at $5.83M in Q1 2019. 160 funds tracked by Wall St. Rank hold ENTA as of Q3 2022.

Acuta Capital Partners reported no remaining Enanta Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Acuta Capital Partners sold 27,500 Enanta Pharmaceuticals shares in Q3 2022, an estimated $1.3M.
Acuta Capital Partners first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 4 quarters.
Acuta Capital Partners's Enanta Pharmaceuticals position peaked at $5.83M in Q1 2019.
160 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2022.

Based on Acuta Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.